A phase II clinical trial found that twice-yearly injections of the anti-RANKL drug denosumab inhibited progression of bone erosion in RA patients with active erosive disease but demonstrated no effect on disease activity (211). The gene discussed is TNFSF11; the disease is rheumatoid arthritis.